Tags

Type your tag names separated by a space and hit enter

Hyperhomocysteinemia in L-dopa treated Parkinson's disease patients: effect of cobalamin and folate administration.
Eur J Neurol. 2005 May; 12(5):365-8.EJ

Abstract

Homocysteine (Hcy) is a risk factor for vascular diseases, cognitive impairment and dementia. L-dopa treatment may represent an acquired cause of hyperhomocysteinemia (HHcy), as evidenced by studies in rats as well as in Parkinson's disease (PD) patients. Folate and cobalamin status also seems to influence the effects of L-dopa on plasma Hcy levels; therefore B-vitamins supplementation has been proposed to reduce the HHcy in L-dopa treated PD patients. Plasma Hcy, folate, and cobalamin levels were evaluated in 20 PD patients treated with L-dopa in the baseline condition and following a 5-week period of treatment with cobalamin and folate; results were compared with 35 controls. Analysis of data revealed that Hcy levels were higher in L-dopa treated PD patients when compared with age- and sex-matched controls and that supplementation of the diet with cobalamin and folate is effective in reducing Hcy concentrations; these findings may have important implications in the treatment of PD patients who are potentially at risk for vascular diseases and cognitive impairment or dementia.

Authors+Show Affiliations

Department of Neurological Sciences, University of Bari, Ospedale Policlinico, Bari, Italy. lamberti@neurol.uniba.itNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

15804266

Citation

Lamberti, P, et al. "Hyperhomocysteinemia in L-dopa Treated Parkinson's Disease Patients: Effect of Cobalamin and Folate Administration." European Journal of Neurology, vol. 12, no. 5, 2005, pp. 365-8.
Lamberti P, Zoccolella S, Armenise E, et al. Hyperhomocysteinemia in L-dopa treated Parkinson's disease patients: effect of cobalamin and folate administration. Eur J Neurol. 2005;12(5):365-8.
Lamberti, P., Zoccolella, S., Armenise, E., Lamberti, S. V., Fraddosio, A., de Mari, M., Iliceto, G., & Livrea, P. (2005). Hyperhomocysteinemia in L-dopa treated Parkinson's disease patients: effect of cobalamin and folate administration. European Journal of Neurology, 12(5), 365-8.
Lamberti P, et al. Hyperhomocysteinemia in L-dopa Treated Parkinson's Disease Patients: Effect of Cobalamin and Folate Administration. Eur J Neurol. 2005;12(5):365-8. PubMed PMID: 15804266.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Hyperhomocysteinemia in L-dopa treated Parkinson's disease patients: effect of cobalamin and folate administration. AU - Lamberti,P, AU - Zoccolella,S, AU - Armenise,E, AU - Lamberti,S V, AU - Fraddosio,A, AU - de Mari,M, AU - Iliceto,G, AU - Livrea,P, PY - 2005/4/5/pubmed PY - 2005/5/21/medline PY - 2005/4/5/entrez SP - 365 EP - 8 JF - European journal of neurology JO - Eur J Neurol VL - 12 IS - 5 N2 - Homocysteine (Hcy) is a risk factor for vascular diseases, cognitive impairment and dementia. L-dopa treatment may represent an acquired cause of hyperhomocysteinemia (HHcy), as evidenced by studies in rats as well as in Parkinson's disease (PD) patients. Folate and cobalamin status also seems to influence the effects of L-dopa on plasma Hcy levels; therefore B-vitamins supplementation has been proposed to reduce the HHcy in L-dopa treated PD patients. Plasma Hcy, folate, and cobalamin levels were evaluated in 20 PD patients treated with L-dopa in the baseline condition and following a 5-week period of treatment with cobalamin and folate; results were compared with 35 controls. Analysis of data revealed that Hcy levels were higher in L-dopa treated PD patients when compared with age- and sex-matched controls and that supplementation of the diet with cobalamin and folate is effective in reducing Hcy concentrations; these findings may have important implications in the treatment of PD patients who are potentially at risk for vascular diseases and cognitive impairment or dementia. SN - 1351-5101 UR - https://www.unboundmedicine.com/medline/citation/15804266/Hyperhomocysteinemia_in_L_dopa_treated_Parkinson's_disease_patients:_effect_of_cobalamin_and_folate_administration_ L2 - https://doi.org/10.1111/j.1468-1331.2004.00973.x DB - PRIME DP - Unbound Medicine ER -